The largest database of trusted experimental protocols
> Disorders > Neoplastic Process > Cervical Cancer

Cervical Cancer

Cervical cancer is a type of cancer that begins in the cervix, the lower, narrow part of the uterus.
This malignant neoplasm is often caused by persistent infection with certain types of human papillomavirus (HPV).
Early-stage cervical cancer may not cause symptoms, but later-stage disease can lead to abnormal vaginal bleeding, pelvic pain, and other complications.
Effective screening and treatment options are available to help prevent and manage cervical cancer, making it an important area of oncologic research and clinical practice.

Most cited protocols related to «Cervical Cancer»

RNA was extracted, converted into mRNA libraries, and paired-end sequenced (paired 50 nt reads) on Illumina HiSeq 2000 Genome Analyzers as previously described5 (link). RNA reads were aligned to the hg19 genome assembly using Mapsplice v12_0760 (link). Gene expression was quantified for the transcript models corresponding to the TCGA GAF2.1 (https://tcga-data.nci.nih.gov/docs/GAF/GAF.hg19.June2011.bundle/outputs/TCGA.hg19.June2011.gaf.) using RSEM461 (link) and normalized within a sample to a fixed upper quartile. To predict whether a cancer sample was from the cervix or the uterus, the data matrix of normalized gene-level RSEM values from 170 UCEC samples was merged with the data matrix from the Core Set (n=178) of cervical cancers. This merged dataset was then randomly split into a training set (87 CESC samples; 86 UCEC samples) and a test set (91 CESC samples; 84 UCEC samples). A sample was predicted to be CESC if the t-statistic vs. UCEC was significant (p<0.05), but was not significantly different from the CESC mean (and vice versa for the UCEC prediction). A data matrix of RSEM values from 178 CESC, 170 UCEC, and 279 HNSC samples was used to identify expression patterns across the 3 cancer types. The gene expression matrix was further filtered to only include the top 25% most variable genes by mean absolute deviation (n=4,039 genes).
Publication 2017
Cervical Cancer Cervix Uteri Gene Expression Genes Genome Malignant Neoplasms RNA, Messenger Uterus
HBM and TPB constructs were assessed with multiple items and were drawn from previous research whenever possible (see Table 1 for example items and the electronic supplementary material (ESM) for the complete list of measures). HBM constructs included perceived susceptibility to [35 (link)] and perceived severity of genital HPV infection, cervical cancer, and genital warts, perceived benefits of HPV vaccination [36 ], and perceived barriers to HPV vaccination [22 (link)]. Perceived barriers included vaccine cost and concerns about vaccine safety and side effects. Cost was not combined with safety/side effects concerns into a single latent factor because items reflected distinct barriers [32 ]. Whether a doctor or other health care provider had ever recommended the HPV vaccine served as a cue to action.
TPB constructs included attitudes, subjective norms, self-efficacy, and intentions. Attitudes toward HPV vaccination were assessed with the same four items used to assess perceived benefits [35 (link)]. Subjective norms reflected the product of normative beliefs for HPV vaccination (i.e., the extent to which their parents, doctor, and best friend think they should be vaccinated) and general motivations to comply with the recommendations of these individuals [33 (link), 37 (link)]. The self-efficacy construct reflected participants’ confidence in their ability to receive the vaccine despite potential barriers (e.g., expense, pain) [38 (link)]. Intentions to receive the HPV vaccine were assessed with five items that had been validated in previous research [33 (link)–34 (link)].
Publication 2012
Cervical Cancer Condylomata Acuminata factor A Friend Genitalia Health Personnel Human Papilloma Virus Vaccine Motivation Pain Papillomavirus Infections, Human Parent Physicians Safety Self Confidence Susceptibility, Disease Vaccines
For the management guidelines, we chose CIN 3+ as the best surrogate for cancer risk. The definition of CIN 3+ as used in these guidelines includes CIN 3, AIS, and the rare cases of invasive cervical cancer that are found in screening programs. These management guidelines consider CIN 3+ risk at the time point relevant for the clinical action being considered—Clinical Action Thresholds for colposcopy and treatment consider immediate risks of CIN 3+, whereas longer-term surveillance recommendations use 5-year risks.
CIN3+ was chosen as an endpoint instead of cancer because cancer is uncommon in the United States, and risk is profoundly decreased by precursor treatment. Cancers that are found in robust screening programs may represent cancers already prevalent at first screening, rare instances of aggressive or HPV-negative tumors not detectable by screening, or false negative results.24 (link) CIN 3+ was chosen instead of CIN 2+ because it is a more pathologically reproducible diagnosis,25 (link) the HPV type distribution in CIN 3+ lesions more closely approximates that of invasive cervical cancers than the larger range of types found in CIN 2,15 (link)–18 (link),26 (link) and CIN 2 has appreciable regression rates in the absence of treatment.27 (link)–29 (link) The choice of CIN 3+ does have some limitations, as even among CIN 3/AIS lesions, risks of progression to cancer differ. Glandular lesions including AIS, lesions with HPV 16 and 18 infections, and those occurring in older patients have higher cancer risks than HPV-negative lesions and those occurring in younger patients.30 (link)Different nomenclatures for cervical histopathology are in use in the United States. The LAST Project and the WHO recommend a 2-tiered terminology (histologic LSIL/HSIL) for reporting histopathology of HPV-associated squamous lesions, similar to the Bethesda system used for reporting cervical cytology.31 (link),32 However, the CIN nomenclature is still commonly used, and data used to generate this set of guidelines relied on CIN nomenclature. Although no direct correlation is possible without use of the p16 biomarker, histologic HSIL is similar but not identical to CIN 2/3.33 (link)
Publication 2020
Biological Markers Cervical Cancer Cervical Intraepithelial Neoplasia, Grade III Colposcopy Cytological Techniques Diagnosis Disease Progression High-Grade Squamous Intraepithelial Lesions Human papillomavirus 16 Infection Low-Grade Squamous Intraepithelial Lesions Malignant Neoplasms Neck Neoplasms Patients Youth
Human hepatoma HepG2 cell line was acquired from ATCC China. The cells were cultivated in RPMI 1640 at 37 °C with 5% CO2 in a moist environment. RPMI was used as per Nasr et al.25 (link), instead of the regular DMEM media. RPMI 1640 was enriched with 10% fetal bovine serum for cytotoxicity assays along with 2 mM L-glutamine, 50 UI/mL penicillin, and 50 UI/mL streptomycin31 (link),32 (link). After every 3 days, the medium was replaced. Cell cultures which have attained confluency were dislodged using trypsin, and the cells were planted into 96-well plates at a density of 106 cells/ml. Before being exposed to cubosomes, the cultures were retained at 37 °C for 24 h to allow the cells to achieve confluency and attach to the well plates. These cultured cells were utilized for cytotoxicity and impedance studies.
Human cervical cancer cells HeLa (obtained from ATCC, China), for the fluorescent studies, were obtained from ATCC and cultured in a combination of Eagle’s minimum essential medium (Sigma-Aldrich, China) with 10% fetal bovine serum in an incubator with humidified air or 5% CO2 at 37 °C. Every 3 days media was renewed, and when reaching 90% confluence cells were passed.
Publication 2020
Biological Assay Cell Culture Techniques Cells Cervical Cancer Cultured Cells Culture Media Cytotoxin Eagle Fetal Bovine Serum Glutamine HeLa Cells Hepatocellular Carcinomas Hep G2 Cells Homo sapiens Penicillins Trypsin
A primary objective of this research was to determine the sensitivity of SaTScan results to the maximum-size parameter. It is important to reiterate that the maximum-size parameter can be either the percentage of the total population at risk or the geographic size of the circle. We use the former because it is the default setting in SaTScan. To understand the sensitivity of SaTScan results to the maximum-size parameter, we ran the SaTScan spatial scan statistic on the cervical cancer dataset fifty times, starting with a maximum-size of 1% and increasing the parameter by an interval of 1 percentage point with each run until reaching the default value maximum-size value of 50%. For each run, we set the number of Monte Carlo replications to 999. The SaTScan software allows users to set the maximum-size in two ways: (1) through restriction of the upper limits of the maximum-size parameter before running the scan or (2) through retention of the default maximum-size of 50%, but selecting for the software to report only circles with a maximum-size value below the desired value. We adopted the second method to avoid pre-selection bias, as recommended by Kulldorff [11 ]. The output for each SaTScan run produces a place ID for each identified cluster; the FIPS code was used as the place ID for this research. The FIPS code at the county level is a five-digit textual code that uniquely identifies counties and county equivalents in the United States. The user can load the files of the fifty SaTScan results into VIT as a batch by specifying the folder where the files are stored in the computer. They are examined in tabular form using the interactive user interface shown in Figure 8. Once the results have been loaded into the VIT's tabular interface, an analyst can interactively investigate each cluster or the individual counties. By selecting one or multiple cluster(s) in the tabular interface, the analyst can select and highlight the cluster(s) on the choropleth map, blurring those counties not included in the selection. We drew a circle around the boundary of each cluster for illustration purposes only; this feature is not implemented in VIT. Specific details (e.g., SMR, p-value, population, etc) about each cluster and individual counties can be interactively retrieved from the map and the tabular interface.
Publication 2008
Cervical Cancer DNA Replication Fingers Hypersensitivity Radionuclide Imaging Retention (Psychology)

Most recents protocols related to «Cervical Cancer»

Example 18

Demonstrating the Selectivity of Stem Cell Derived Neutrophils CKA for Cancer Cells

Neutrophils derived from CD34+ stem cells of three different donors were tested for CKA against both HeLa cells (cervical cancer), PANC-1 cells (pancreatic cancer) as well as non-cancer MCF-12F cells (normal breast epithelial cells).

FIG. 9 shows the maximum percentage cytotoxicity recorded by the CKA assay (xCELLigence assay—carried out for up to 45 hours) against each cancer cell type and non-cancer cell type for donors LC267, LC268 and LC269. Advantageously, SCDNs were highly selective for cancer cells showing minimal impact on non-cancer cells. Similarly to FIG. 3 showing DDN from the same donors, SCDNs from donor LC269 had the highest CKA with LC268 second, and LC267 showing the lowest CKA. Thus, it can be concluded that CKA is a genetically-defined rather than epigenetically-defined trait.

Similar results were obtained for SCDNs of donors LC252, LC253 and LC254 (FIG. 10).

Patent 2024
Biological Assay Breast Cells Cervical Cancer Cytotoxin Donors Epithelial Cells HeLa Cells Malignant Neoplasms Neutrophil Pancreatic Cancer Stem, Plant Stem Cells Tissue Donors

Example 3

A female patient with cervical carcinoma is treated with combined radiation therapy and chemotherapy+NVX-108. Radiation dosage is 45 Gray (Gy) in 20 fractions followed by low dose-rate intracavitary application of 30 Gy to the cervical region. Chemotherapy consists of intravenous cisplatin 40 mg/m2 every week for up to 6 weekly cycles. The patient is administered a bolus IV dose of 0.2 cc/kg NVX-108 (2% w/vol DDFPe) 60 minutes prior to each dose of radiation. Follow-up shows complete response to treatment.

Patent 2024
Cervical Cancer Cisplatin Neck NVX-108 Oxygen Patients Pharmacotherapy Radiotherapy Woman
Not available on PMC !

Example 13

Demonstrating CKA of Donor Derived Neutrophils on Different Cancer Cell Types

Neutrophils isolated from five different donors were tested for CKA against both HeLa cells (cervical cancer) and PANC-1 cells (pancreatic cancer).

FIG. 4 shows the maximum percentage cytotoxicity recorded by the CKA assay (xCELLigence assay) against each cancer cell type and for the different donors. The percentage cytotoxicity against pancreatic cancer cells was higher, which was surprising given that pancreatic cancer is typically one of the most difficult cancers to treat. Again, Donor Derived Neutrophils (DDNs) from different donors were shown to have differential CKA.

Patent 2024
Biological Assay Cervical Cancer Cytotoxin Donors HeLa Cells Malignant Neoplasms Neutrophil Pancreatic Cancer Tissue Donors

Example 4

Cells were plated at 6,000 cells/well in a 96-well plate and treated with the indicated concentration of zafirlukast 24 hours later. Cells were allowed to grow for an additional 24 hours before alterations in growth were measured by the PrestoBlue cell proliferation assay in triplicate. Fluorescence readings with an excitation at 570 nm and emission of 600 nm were collected and treated samples were converted to a percentage of the untreated controls.

OVCar8 (human ovarian cancer cell line), HCT116 (human colon cancer), HeLa (cervical cancer cell line) and MDA-MB-231 (breast cancer cell line) cell lines were examined for their ability to inhibit cell proliferation. OVCar8 and HCT116 cells exhibited an IC50 in the 5-10 μM range. HeLa cervical cancer cells and MDA-MB-231 breast cancer lines were less sensitive. Table 1 illustrates the results of a cell proliferation assay testing zafirlukast against OVCar8 cells, HCT116 cells, HeLa cells and MDA-MB-231 cells.

TABLE 1
Cell LineTumor TypeIC50
HCT116Colon Cancer5 μM (±2 μM)
OVCar8Ovarian Cancer6 μM (±2 μM)
HeLaCervical Cancer30 μM (±5 μM) 
MDA-MB-231Breast Cancer100 μM (±7 μM) 

Patent 2024
Biological Assay Cancer of Colon Cardiac Arrest Cell Lines Cell Proliferation Cells Cervical Cancer Colonic Neoplasms Fluorescence HCT116 Cells HeLa Cells Homo sapiens Isomerase Malignant Neoplasm of Breast Malignant Neoplasms MCF-7 Cells MDA-MB-231 Cells Neoplasms Ovarian Cancer Sulfhydryl Compounds Inhibitors zafirlukast
From June 2019 to April 2021, patients with metastatic cervical cancer who received ICI retreatment at the Cancer Center, Union Hospital, Huazhong University of Science and Technology, Wuhan, China, were enrolled in this study. The inclusion criteria were as follows: (1) pathologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix; (2) metastatic cervical cancer; (3) achieved complete response (CR), partial response (PR), or stable disease (SD) as the best clinical response to first-course immunotherapy; (4) received at least two cycles of retreatment with triplet combination therapy including PD-1 inhibitor, chemotherapy, and antiangiogenic agent; (5) had at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; and (6) Eastern Cooperative Oncology Group performance score of 1 or less. Patients who did not have the follow-up data were excluded from the analyses. Baseline clinicopathological data, including age, histology, initial stage, metastatic sites, primary surgery, lines of prior systemic treatment, and immunotherapy regimens, were retrieved from medical records.
This retrospective study was conducted in accordance with the principles embodied in the 1964 Declaration of Helsinki and was approved by the Ethics Committee of the Union Hospital of the Huazhong University of Science and Technology (20220023). Informed consent was obtained from all the participants or their legal guardians if the participants cannot write.
Publication 2023
Adenocarcinoma Angiogenesis Inhibitors Cervical Cancer Combined Modality Therapy Ethics Committees, Clinical Immunotherapy Legal Guardians Malignant Neoplasms Neck Neoplasm Metastasis Neoplasms Operative Surgical Procedures Patients Pharmacotherapy Programmed Cell Death Protein 1 Inhibitor Retreatments Squamous Cell Carcinoma Treatment Protocols Triplets Vitelliform Macular Dystrophy

Top products related to «Cervical Cancer»

Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco
Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.
Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama
Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.
Sourced in United States, China, Germany, United Kingdom, Japan, France, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Israel, Sweden, Denmark, Macao, Brazil, Ireland, India, Austria, Netherlands, Holy See (Vatican City State), Poland, Norway, Cameroon, Hong Kong, Morocco, Singapore, Thailand, Argentina, Taiwan, Province of China, Palestine, State of, Finland, Colombia, United Arab Emirates
RPMI 1640 medium is a commonly used cell culture medium developed at Roswell Park Memorial Institute. It is a balanced salt solution that provides essential nutrients, vitamins, and amino acids to support the growth and maintenance of a variety of cell types in vitro.
Sourced in United States, China, Germany, United Kingdom, Canada, Japan, France, Italy, Switzerland, Australia, Spain, Belgium, Denmark, Singapore, India, Netherlands, Sweden, New Zealand, Portugal, Poland, Israel, Lithuania, Hong Kong, Argentina, Ireland, Austria, Czechia, Cameroon, Taiwan, Province of China, Morocco
Lipofectamine 2000 is a cationic lipid-based transfection reagent designed for efficient and reliable delivery of nucleic acids, such as plasmid DNA and small interfering RNA (siRNA), into a wide range of eukaryotic cell types. It facilitates the formation of complexes between the nucleic acid and the lipid components, which can then be introduced into cells to enable gene expression or gene silencing studies.
Sourced in United States, China
The CaSki is a cell line derived from a human cervical carcinoma. It is used for research purposes in the field of virology and oncology.
Sourced in United States, China, United Kingdom, Germany, France, Canada, Japan, Australia, Italy, Switzerland, Belgium, New Zealand, Austria, Netherlands, Israel, Sweden, Denmark, India, Ireland, Spain, Brazil, Norway, Argentina, Macao, Poland, Holy See (Vatican City State), Mexico, Hong Kong, Portugal, Cameroon
RPMI 1640 is a common cell culture medium used for the in vitro cultivation of a variety of cells, including human and animal cells. It provides a balanced salt solution and a source of essential nutrients and growth factors to support cell growth and proliferation.
Sourced in United States, United Kingdom, China, Germany, France, Japan, Italy, Switzerland, Sweden, India, Canada, Egypt, Australia, Holy See (Vatican City State), Brazil
MCF-7 is a cell line derived from human breast adenocarcinoma. It is an adherent epithelial cell line that can be used for in vitro studies.

More about "Cervical Cancer"

Cervical cancer is a type of malignant neoplasm that originates in the cervix, the lower, narrow part of the uterus.
This form of cancer is often caused by persistent infection with certain types of human papillomavirus (HPV), a common sexually transmitted virus.
In the early stages, cervical cancer may not produce any symptoms, but as the disease progresses, it can lead to abnormal vaginal bleeding, pelvic pain, and other complications.
Effective screening and treatment options are available to help prevent and manage cervical cancer, making it an important area of oncologic research and clinical practice.
Screening methods like Pap smears and HPV tests can detect precancerous changes in the cervix, allowing for early intervention and prevention.
Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches, depending on the stage and severity of the cancer.
Researchers continue to explore various aspects of cervical cancer, such as the role of cell culture models like CaSki and MCF-7 cells, as well as the use of media like RPMI 1640 and DMEM to support cancer cell growth and study.
Additionally, techniques like Lipofectamine 2000 transfection are employed to investigate gene expression and cellular mechanisms in cervical cancer cells.
Understanding the complexities of cervical cancer and the advancements in its prevention and management is crucial for healthcare professionals, researchers, and the general public.
By staying informed about the latest developments in this field, we can work towards reducing the burden of this disease and improving outcomes for those affected.